Mendus AB ("Mendus" publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies for myeloid blood cancers, today announced that the first patient has been enrolled in the VITAL-CML trial, w ...
Stocktwits on MSN
SLS vs. TERN: Which pharma stock has more upside as Merck eyes $6B cancer bet ahead of Keytruda patent cliff
SLS and TERN are advancing leukemia therapies, with TERN-701 targeting CML and GPS positioned as a Phase 3 maintenance immunotherapy in AML. ・Sellas is approaching a Phase 3 Regal survival readout, a ...
Researchers recently calculated the estimated savings over a 30-year period with regard to CML patients who attempt to get off their TKI therapy. In what they referred to as a 'conservative' estimate, ...
Enliven Therapeutics Inc. (NASDAQ:ELVN) is one of the 11 Stocks With 3x-5x Returns This Year. Enliven Therapeutics has seen ...
Researchers have found that the clinical application of BCR::ABL1 digital PCR can reliably quantify stable deep molecular remission of chronic myeloid leukemia (CML), which will help to determine for ...
CML is marked by the Philadelphia Chromosome and BCR-ABL1 gene, causing excessive white blood cell production. Diagnosis includes bone marrow biopsy, cytogenetics, and qPCR to monitor the BCR-ABL1 ...
It is important to distinguish de novo CML-BP from Ph-positive ALL before allogeneic hematopoietic cell transplantation. The effect of BCR::ABL1 mutation status on outcomes of hematopoietic cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results